StockNews.AI
SEER
StockNews.AI
117 days

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

1. Seer will report Q1 2025 financial results on May 13. 2. A conference call will be webcasted live on the company's website. 3. Seer's Proteograph suite revolutionizes proteomic analysis in laboratories. 4. The product suite is designed for efficient, decentralized lab integration.

Earnings
-1.01%Current Return
VS
+0.73%S&P 500
$1.9904/24 04:17 PM EDTEvent Start
$1.9704/25 10:25 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings report may provide clarity on financial health and market positioning. Previous earnings reports have had varying impacts on stock performance.

How important is it?

The financial results can directly influence investor sentiment and market confidence. Earnings releases are critical for shaping price direction.

Why Short Term?

The earnings call on May 13 will provide immediate insights into performance. Historical precedents indicate quarterly results often drive near-term stock movement.

Related Companies

LMNKAMER
April 24, 2025 16:05 ET  | Source: Seer, Inc. REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio. Media Contact:Patrick Schmidt pr@seer.bio Investor Contact:Carrie Mendivilinvestor@seer.bio

Related News